Underrecognized comorbidities of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 10, Issue , 2015, Pages 1331-1341

  Miłkowska Dymanowska, Joanna ^a,b   Białas, Adam J ^a,b   Zalewska Janowska, Anna ^c   Górski, Paweł ^a,b   Piotrowski, Wojciech J ^a,b  

^a Department of Pneumology and Allergy 1st Chair of Internal Medicine   (Poland)

^b Healthy Aging Research Centre (HARC)   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Comorbidities; COPD; Endocrinological disorders; GERD; Rhinosinusitis

Indexed keywords

ASYMPTOMATIC DISEASE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; CONGENITAL SKIN DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; GALLBLADDER DISEASE; GASTROESOPHAGEAL REFLUX; GLAUCOMA; HEART FAILURE; HUMAN; OBESITY; PANCREAS DISEASE; PATHOGENESIS; QUALITY OF LIFE; REVIEW; RHINOSINUSITIS; WRINKLE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTOR;

COMORBIDITY; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS;

EID: 84937552102     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S82420     Document Type: Review

References (104)

1. Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med. 2011;183(9):1129-1137.
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-1185.
3. Boros PW, Lubiński W. Health state and the quality of life in patients with chronic obstructive pulmonary disease in Poland: a study using the EuroQoL-5D questionnaire. Pol Arch Med Wewn. 2012;122(3):73-81.
4. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10(12):2794-2800.
5. Glynn LG, Valderas JM, Healy P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract. 2011;28(5):516-523.
6. Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani LG. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med. 2011;17 Suppl 1:S35-S41.
7. McDaid O, Hanly MJ, Richardson K, Kee F, Kenny RA, Savva GM. The effect of multiple chronic conditions on self-rated health, disability and quality of life among the older populations of Northern Ireland and the Republic of Ireland: a comparison of two nationally representative cross-sectional surveys. BMJ Open. 2013;3(6). pii: e002571.
8. Frei A, Muggensturm P, Putcha N, et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. J Clin Epidemiol. 2014;67(8):904-911.
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [homepage on the Internet]. Global strategy for the diagnosis, management, and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2015. Leuven (Belgium), Marburg (Germany). Available from: http://web.archive.org/web/20150227051533/http://www.goldcopd.org. Accessed February 27, 2015.
10. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173-180.
11. Amsellem V, Gary-Bobo G, Marcos E, et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(12):1358-1366.
12. Ito K, Colley T, Mercado N. Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease. Int J Chron Obstruct Pulmon Dis. 2012;7:641-652.
13. Barnes PJ. Mechanisms of development of multimorbidity in the elderly. Eur Respir J. 2015;45(3):790-806.
14. Papaioannou AI, Mazioti A, Kiropoulos T, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med. 2010;104(2):275-282.
15. Salanitro AH, Ritchie CS, Hovater M, et al. Inflammatory biomarkers as predictors of hospitalization and death in community-dwelling older adults. Arch Gerontol Geriatr. 2012;54(3):e387-e391.
16. Moy ML, Teylan M, Danilack VA, Gagnon DR, Garshick E. An index of daily step count and systemic inflammation predicts clinical outcomes in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(2):149-157.
17. Mannino DM, Valvi D, Mullerova H, Tal-Singer R. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD. 2012;9(4):359-366.
18. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728-735.
19. Fu JJ, McDonald VM, Gibson PG, Simpson JL. Systemic inflammation in older adults with asthma-COPD overlap syndrome. Allergy Asthma Immunol Res. 2014;6(4):316-324.
20. Garcia-Aymerich J, Gómez FP, Benet M, et al; PAC-COPD Study Group. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430-437.
21. García-Olmos L, Salvador CH, Alberquilla Á, et al. Comorbidity patterns in patients with chronic diseases in general practice. PLoS One. 2012;7(2):e32141.
22. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.
23. Halawi AM, Smith SS, Chandra RK. Chronic rhinosinusitis: epidemiology and cost. Allergy Asthma Proc. 2013;34(4):328-334.
24. Tomassen P, Newson RB, Hoffmans R, et al. Reliability of EP3OS symptom criteria and nasal endoscopy in the assessment of chronic rhinosinusitis - a GA² LEN study. Allergy. 2011;66(4):556-561.
25. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe - an underestimated disease. A GA² LEN study. Allergy. 2011;66(9):1216-1223.
26. Chandra RK, Lin D, Tan B, et al. Chronic rhinosinusitis in the setting of other chronic inflammatory diseases. Am J Otolaryngol. 2011;32(5):388-391.
27. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106(5 Suppl):S201-S205.
28. Nutku E, Toda M, Hamid QA. Rhinitis, nasal polyposis and asthma: pathological aspects. In: Wallaert B, Chanez P, Godard P, editors. The Nose and Lung Diseases. European Respiratory Monograph. 2001;6:115-142.
29. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope. 2003;113(7):1199-1205.
30. Roberts NJ, Lloyd-Owen SJ, Rapado F, et al. Relationship between chronic nasal and respiratory symptoms in patients with COPD. Respir Med. 2003;97(8):909-914.
31. Hurst JR, Wilkinson TM, Donaldson GC, Wedzicha JA. Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med. 2004;98(8):767-770.
32. Hens G, Vanaudenaerde BM, Bullens DM, et al. Sinonasal pathology in nonallergic asthma and COPD: 'united airway disease' beyond the scope of allergy. Allergy. 2008;63(3):261-267.
33. Kelemence A, Abadoglu O, Gumus C, Berk S, Epozturk K, Akkurt I. The frequency of chronic rhinosinusitis/nasal polyp in COPD and its effect on the severity of COPD. COPD. 2011;8(1):8-12.
34. Nicola ML, Carvalho HB, Yoshida CT, et al. Young "healthy" smokers have functional and inflammatory changes in the nasal and the lower airways. Chest. 2014;145(5):998-1005.
35. Lachanas VA, Tsea M, Tsiouvaka S, Exarchos ST, Skoulakis CE, Bizakis JG. The effect of active cigarette smoking on Sino-Nasal Outcome Test in 127 subjects without rhinologic disease. A prospective study. Clin Otolaryngol. 2015;40(1):56-59.
36. Uhliarova B, Adamkov M, Svec M, Calkovska A. The effect of smoking on CT score, bacterial colonization and distribution of inflammatory cells in the upper airways of patients with chronic rhinosinusitis. Inhal Toxicol. 2014;26(7):419-425.
37. Pace E, Ferraro M, Di Vincenzo S, et al. Oxidative stress and innate immunity responses in cigarette smoke stimulated nasal epithelial cells. Toxicol In Vitro. 2014;28(2):292-299.
38. Virgin FW, Azbell C, Schuster D, et al. Exposure to cigarette smoke condensate reduces calcium activated chloride channel transport in primary sinonasal epithelial cultures. Laryngoscope. 2010;120(7):1465-1469.
39. Piotrowska VM, Piotrowski WJ, Kurmanowska Z, Marczak J, Górski P, Antczak A. Rhinosinusitis in COPD: symptoms, mucosal changes, nasal lavage cells and eicosanoids. Int J Chron Obstruct Pulmon Dis. 2010;5:107-117.
40. Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest. 2005;127(4):1219-1226.
41. Vachier I, Vignola AM, Chiappara G, et al. Inflammatory features of nasal mucosa in smokers with and without COPD. Thorax. 2004;59(4):303-307.
42. Daniell HW. Smoker's wrinkles. A study in the epidemiology of "crow's feet". Ann Intern Med. 1971;75(6):873-880.
43. Yin L, Morita A, Tsuji T. Alterations of extracellular matrix induced by tobacco smoke extract. Arch Dermatol Res. 2000;292(4):188-194.
44. Lahmann C, Bergemann J, Harrison G, Young AR. Matrix metalloproteinase-1 and skin ageing in smokers. Lancet. 2001;357(9260):935-936.
45. Knuutinen A, Kokkonen N, Risteli J, et al. Smoking affects collagen synthesis and extracellular matrix turnover in human skin. Br J Dermatol. 2002;146(4):588-594.
46. Just M, Ribera M, Monsó E, Lorenzo JC, Ferrándiz C. Effect of smoking on skin elastic fibres: morphometric and immunohistochemical analysis. Br J Dermatol. 2007;156(1):85-91.
47. Ortiz A, Grando SA. Smoking and the skin. Int J Dermatol. 2012;51(3):250-262.
48. Bosset S, Bonnet-Duquennoy M, Barré P, et al. Photoageing shows histological features of chronic skin inflammation without clinical and molecular abnormalities. Br J Dermatol. 2003;149(4):826-835.
49. Iddamalgoda A, Le QT, Ito K, Tanaka K, Kojima H, Kido H. Mast cell tryptase and photoaging: possible involvement in the degradation of extra cellular matrix and basement membrane proteins. Arch Dermatol Res. 2008;300 Suppl 1:S69-S76.
50. Kaukinen A, Fitzgibbon A, Oikarinen A, Hinkkanen L, Viinikanoja M, Harvima IT. Increased numbers of tryptase-positive mast cells in the healthy and sun-protected skin of tobacco smokers. Dermatology. 2014;229(4):353-358.
51. Chung JH, Lee SH, Youn CS, et al. Cutaneous photodamage in Koreans: influence of sex, sun exposure, smoking, and skin color. Arch Dermatol. 2001;137(8):1043-1051.
52. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax. 2006;61(7):568-571.
53. Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012;67(7):606-612.
54. Just M, Monsó E, Ribera M, Lorenzo JC, Morera J, Ferrandiz C. Relationships between lung function, smoking and morphology of dermal elastic fibres. Exp Dermatol. 2005;14(10):744-751.
55. Müller KC, Paasch K, Feindt B, et al. In contrast to lung fibroblasts - no signs of senescence in skin fibroblasts of patients with emphysema. Exp Gerontol. 2008;43(7):623-628.
56. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol. 2010;2010:917108.
57. Lee EJ, Park JH. Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics Inform. 2013;11(4):224-229.
58. Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol. 2006;19(11):1437-1445.
59. Wu L, Ma L, Nicholson LF, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med. 2011;105(3):329-336.
60. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011;37(3):516-522.
61. Gopal P, Reynaert NL, Scheijen JL, et al. Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. Eur Respir J. 2014;43(2):430-438.
62. Hoonhorst SJ, Lo Tam Loi AT, Hartman JE, et al. Advanced glycation end products in the skin are enhanced in COPD. Metabolism. 2014;63(9):1149-1156.
63. Palkovits S, Lasta M, Told R, et al. Retinal oxygen metabolism during normoxia and hyperoxia in healthy subjects. Invest Ophthalmol Vis Sci. 2014;55(8):4707-4713.
64. Celik C, Tokgöz O, Serifoğlu L, Tor M, Alpay A, Erdem Z. Color Doppler evaluation of the retrobulbar hemodynamic changes in chronic obstructive pulmonary disease: COPD and retrobulbar hemodynamic changes. Ultrason Imaging. 2014;36(3):177-186.
65. Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther. 2010;23(2):65-70.
66. Nesher R; Israel Glaucoma Screening Group. Prevalence of increased intraocular pressure and optic disk cupping: multicenter glaucoma screening in Israel during the 2009 and 2010 World Glaucoma Weeks. Isr Med Assoc J. 2014;16(8):483-486.
67. Huerta C, García Rodríguez LA, Möller CS, Arellano FM. The risk of obstructive airways disease in a glaucoma population. Pharmacoepidemiol Drug Saf. 2001;10(2):157-163.
68. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099-2107.
69. Zlateva GP, Javitt JC, Shah SN, Zhou Z, Murphy JG. Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population. Retina. 2007;27(9):1292-1299.
70. Klein R, Knudtson MD, Klein BE. Pulmonary disease and age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(6):840-846.
71. Soler N, García-Heredia A, Marsillach J, et al. Paraoxonase-1 is associated with corneal endothelial cell alterations in patients with chronic obstructive pulmonary disease. Invest Ophthalmol Vis Sci. 2013;54(8):5852-5858.
72. Doehner W, Haeusler KG, Endres M, Anker SD, MacNee W, Lainscak M. Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. Respir Med. 2011;105 Suppl 1:S12-S19.
73. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003;46:76s-80s.
74. Sundar IK, Yao H, Huang Y, et al. Serotonin and corticosterone rhythms in mice exposed to cigarette smoke and in patients with COPD: implication for COPD-associated neuropathogenesis. PLoS One. 2014;9(2):e87999.
75. Dimopoulou I, Ilias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism. 2001;50(12):1397-1401.
76. Okutan O, Kartaloglu Z, Onde ME, Bozkanat E, Kunter E. Pulmonary function tests and thyroid hormone concentrations in patients with chronic obstructive pulmonary disease. Med Princ Pract. 2004;13(3):126-128.
77. Karadag F, Ozcan H, Karul AB, Yilmaz M, Cildag O. Correlates of non-thyroidal illness syndrome in chronic obstructive pulmonary disease. Respir Med. 2007;101(7):1439-1446.
78. Mancini A, Corbo GM, Gaballo A, et al. Relationship between plasma antioxidants and thyroid hormones in chronic obstructive pulmonary disease. Exp Clin Endocrinol Diabetes. 2012;120(10):623-628.
79. Balasubramanian V, Naing S. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr Opin Pulm Med. 2012;18(2):112-117.
80. Karakou E, Glynos C, Samara KD, Msaouel P, Koutsilieris M, Vassilakopoulos T. Profile of endocrinological derangements affecting PSA values in patients with COPD. In Vivo. 2013;27(5):641-649.
81. Corbo GM, Di Marco Berardino A, Mancini A, et al. Serum level of testosterone, dihydrotestosterone and IGF-1 during an acute exacerbation of COPD and their relationships with inflammatory and prognostic indices: a pilot study. Minerva Med. 2014;105(4):289-294.
82. Laghi F, Antonescu-Turcu A, Collins E, et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med. 2005;171(7):728-733.
83. Mousavi SA, Kouchari MR, Samdani-Fard SH, Gilvaee ZN, Arabi M. Relationship between serum levels of testosterone and the severity of chronic obstructive pulmonary disease. Tanaffos. 2012;11(3): 32-35.
84. Vertkin AL, Morgunov LI, Shakhmanaev KhA. [Hypogonadism and chronic obstructive pulmonary disease]. Urologiia. 2013;(5):116-118; 120-122. Russian.
85. Chen YC, Lin YH, Chen SH, et al. Epidemiology of adrenal insufficiency: a nationwide study of hospitalizations in Taiwan from 1996 to 2008. J Chin Med Assoc. 2013;76(3):140-145.
86. Martinez CH, Okajima Y, Murray S, et al; COPDGene Investigators. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respir Res. 2014;15:62.
87. Harding SM, Guzzo MR, Richter JE. 24-h esophageal pH testing in asthmatics: respiratory symptom correlation with esophageal acid events. Chest. 1999;115(3):654-659.
88. Emilsson OI, Janson C, Benediktsdóttir B, Júlíusson S, Gíslason T. Nocturnal gastroesophageal reflux, lung function and symptoms of obstructive sleep apnea: Results from an epidemiological survey. Respir Med. 2012;106(3):459-466.
89. Miyazaki M, Nakamura H, Chubachi S, et al; Keio COPD Comorbidity Research (K-CCR) Group. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res. 2014;15:13.
90. Ajmera M, Raval AD, Shen C, Sambamoorthi U. Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:339-348.
91. Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008;63(11):951-955.
92. Boeree MJ, Peters FT, Postma DS, Kleibeuker JH. No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. Eur Respir J. 1998;11(5):1070-1074.
93. Mapel D. Renal and hepatobiliary dysfunction in chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2014;20(2):186-193.
94. Terzano C, Romani S, Paone G, Conti V, Oriolo F. COPD and thyroid dysfunctions. Lung. 2014;192(1):103-109.
95. Divo M, Cote C, de Torres JP, et al; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-161.
96. Kim J, Lee JH, Kim Y, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med. 2013;13:51.
97. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009;136(6):1456-1465.
98. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63-70.
99. Keller CA, Shepard JW, Chun DS, Vasquez P, Dolan GF. Pulmonary hypertension in chronic obstructive pulmonary disease. Multivariate analysis. Chest. 1986;90(2):185-192.
100. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337-349.
101. Gudmundsson G, Gislason T, Janson C, et al. Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir Med. 2006;100(1):87-93.
102. Hanania NA, Müllerova H, Locantore NW, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604-611.
103. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest. 2000;117(5 Suppl 2):346S-53S.
104. Kühl K, Schürmann W, Rief W. Mental disorders and quality of life in COPD patients and their spouses. Int J Chron Obstruct Pulmon Dis. 2008;3(4):727-736.